Neurol. praxi. 2018;19(4):298-301 | DOI: 10.36290/neu.2018.039

Neuropathic pain in a patient with autoimmune polyneuropathy (case report)

MUDr. Nela Kopecká, doc. MUDr. Edvard Ehler, CSc.
Neurologická klinika FZS Univerzity Pardubice a Pardubické krajské nemocnice, Pardubice

Neuropathic pain is a serious problem in patients with systemic disease and leads to significant limitation of the functional status.The case presented here describes patient with idiopathic pulmonary fibrosis with the development of autoimmune neuropathyand neuropathic pain with allodynia following herpes infection of the lungs. Pacient uses high doses of gabapentin in order toachieve relief of neuropatic pain with very good tolerance and without side effects.

Keywords: neuropathic pain, pharmacological treatment, autoimmune neuropathy, allodynia, hyperalgesia

Received: January 26, 2018; Accepted: May 23, 2018; Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopecká N, Ehler E. Neuropathic pain in a patient with autoimmune polyneuropathy (case report). Neurol. praxi. 2018;19(4):298-301. doi: 10.36290/neu.2018.039.
Download citation

References

  1. Akyuz G, Kenis O. Physical therapy modalities and rehabilitation techniques in the management of neuropathic pain. Am J Phys Med Rehabil 2014; 93: 253-259 Go to original source...
  2. Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, Raicher I, Üçeyler N, Sommer C, Bouhassira D. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2016; 15(6): 555-565 Go to original source...
  3. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis,pathophysiological mechanisms, and treatment. Lancet Neurol 2010; 9: 807-819 Go to original source... Go to PubMed...
  4. Bednařík J, Amber Z, Opavský J, Keller O, Rokyta R, Mazanec R, Lejčko J, Kozák J, Suchý M, Pátá M, Kožený P. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol N 2012; 75/108(1): 93-101
  5. Bennett DL, Groves M, Blake J, Holton JL, King RH, Orrell RW, Ginsberg L, Reilly MM. The use of nerve and muscle biopsy in the diagnosis of vasculitis: a 5 year retrospective study. J Neurol Neurosurg Psychiatry 2008; 79(12): 1376-1381 Go to original source...
  6. Haanpää ML, Backonja MM, Bennett MI, Bouhassira D, Cruccu G, Hansson PT, Jensen TS, Kauppila T, Rice AS, Smith BH, Treede RD, Baron R. Assessment of neuropathic pain in primary care. Am J Med 2009; 122: 13-21 Go to original source...
  7. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropatic pain: clinical manifestations and mechanisms. Lancet Neurol 2014; 13: 924-35 Go to original source...
  8. Jongen JL, Hans G, Benzon HT, Huygen F, Hartrick CT. Neuropathic pain and pharmacological treatment. Pain Pract 2014; 14(3): 283-95 Go to original source... Go to PubMed...
  9. Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain 2001; 94(2): 131-2. Go to original source... Go to PubMed...
  10. Šrotová I, Vlčková E, Strakova J, Kincová S, Ryba L, Dušek L, Adamová B, Bednařík J. Validace české verze Neuropathic Pain Symptom Inventory (NPSIcz). Cesk Slov Neurol N 2015; 78/111(1): 45-56
  11. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-5 Go to original source... Go to PubMed...
  12. Walsh M, Mukhtyar C, Mahr A, Herlyn K, Luqmani R, Merkem PA, Jayne DR. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res 2011; 63: 1055-1061 Go to original source...
  13. Wolf J, Schmitt V, Palm F, Grau AJ, Bergner R. Peripheral neuropathy as initial manifestation of primary systemic vasculitides, J Neurol 2013; 260: 1061-1070 Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.